TNXP Tonix Pharmaceuticals Quick Ratio

Stock price action on GURU.Markets helps assess the impact of strict FDA inspections and intellectual property protection on the valuation of Tonix Pharmaceuticals (TNXP), where the indicator stands at 6.62. The business relies on developing therapies for pain and neurology, whose market value depends on patents. Meanwhile, the firm's environmental policy remains formal due to the absence of large-scale manufacturing facilities.

The complex vaccine development logistics of Tonix Pharmaceuticals (TNXP) require constant access to operating funds to maintain its laboratory network. This metric assesses the company's ability to settle short-term obligations using cash and accounts receivable, completely excluding illiquid inventories. An increase in this ratio confirms financial autonomy and reduces the risk of research interruptions. By analyzing the quick ratio, an investor determines the real solvency of the business without accounting for warehouse assets.